Literature DB >> 21066891

[Effect of banxia baizhu tianma decoction on the left ventricular hypertrophy of hypertrophied myocardium in spontaneously hypertensive rat].

Jia-Ye Jiang1, Xian-Zhen Wang, Shan-Shan Luo.   

Abstract

OBJECTIVE: To investigate the changes in renin angiotensin system (RAS) in hypertrophied myocardium of spontaneous hypertensive rat (SHR), and the effect of Banxia Baizhu Tianma Decoction (BBTD) on the changes in haemodynamic parameters and mRNA of signaling molecules of RAS at different periods.
METHODS: Fifty-four male SHRs of 6 weeks old were randomly and equally divided into three groups: the untreated control group, the test group, and the positive control group, and they were treated respectively with distilled water, BBTD and captopril by dissolving in equal volume of water administrated via gavage for 18 weeks. Besides, 18 age matched Wistar-Kyoto (WKY) rats treated with distilled water were allocated in a normal control group. Rats were managed in batches at their age of 18, 24, and 32 weeks old. Rat's hemodynamic parameters were measured through carotid artery catheterization, myocardial pathology was observed, and their mRNA expressions of angiotensin (AGT), angiotensin-converting (ACE) and angiotension-converting 2 (ACE2) were determined by Real-time PCR.
RESULTS: Compared with WKY rats, the arterial pressure and left ventricular mass index (LVMI)in SHR were significantly higher at 18, 24 and 32 weeks respectively (P < 0.01); average cycle rate showed in electrocardiogram was higher (P < 0.05), though the blood stream was similar; mRNA expressions of AGT and ACE in heart tissue were markedly higher (P < 0.01), but that of ACE2 at 18 and 24 weeks were lower (P < 0.01). Compared with untreated SHR, arterial pressure at 18 and 24 weeks was lower (P < 0.05); cardiac muscle structure was improved; LVMI at 24 weeks was improved (P < 0.05); the mRNA expressions of AGT and ACE were suppressed but that of ACE2 increased at 18, 24,and 32 weeks significantly in the test group after BBTD treatment (P < 0.05).
CONCLUSIONS: Changes in RAS in the hypertrophied myocardium of SHR may be one of the molecular mechanisms for hypertension leading to left ventricular hypertrophy. BBTD can improve the hemodynamic parameters, regulate RAS, so as to lower the arterial pressure.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21066891

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  6 in total

1.  Banxia baizhu tianma decoction for essential hypertension: a systematic review of randomized controlled trials.

Authors:  Xingjiang Xiong; Xiaochen Yang; Wei Liu; Bo Feng; Jizheng Ma; Xinliang Du; Pengqian Wang; Fuyong Chu; Jun Li; Jie Wang
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-20       Impact factor: 2.629

2.  Control strategy on hypertension in chinese medicine.

Authors:  Jie Wang; Xingjiang Xiong
Journal:  Evid Based Complement Alternat Med       Date:  2011-12-12       Impact factor: 2.629

3.  Frequency and co-prescription pattern of Chinese herbal products for hypertension in Taiwan: a Cohort study.

Authors:  Pei-Rung Yang; Wei-Tai Shih; Yen-Hua Chu; Pau-Chung Chen; Ching-Yuan Wu
Journal:  BMC Complement Altern Med       Date:  2015-06-06       Impact factor: 3.659

Review 4.  Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science.

Authors:  Xingjiang Xiong; Xiaochen Yang; Yongmei Liu; Yun Zhang; Pengqian Wang; Jie Wang
Journal:  Hypertens Res       Date:  2013-04-04       Impact factor: 3.872

5.  Trends in the treatment of hypertension from the perspective of traditional chinese medicine.

Authors:  Xingjiang Xiong; Xiaochen Yang; Wei Liu; Fuyong Chu; Pengqian Wang; Jie Wang
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-26       Impact factor: 2.629

Review 6.  Neuropharmacological Potential of Gastrodia elata Blume and Its Components.

Authors:  Jung-Hee Jang; Yeonghoon Son; Seong Soo Kang; Chun-Sik Bae; Jong-Choon Kim; Sung-Ho Kim; Taekyun Shin; Changjong Moon
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-12       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.